Marburg virus disease - Rwanda
18 October 2024
Situation at a glance
As of 17 October 2024, a total of 62 Marburg virus disease cases, including 15 deaths (CFR: 24.2%), have been reported in Rwanda, with forty-three recoveries. Contact tracing is underway, with over 800 contacts under follow-up as of 14 October 2024. In October, a surge team from WHO was deployed to support the in-country response across the functions of incident management: epidemiology, health operations, case management, health logistics, vaccines research, partner coordination and infection prevention and control.
Description of the situation
Since the last
Disease Outbreak News on this event was published on 11 October 2024, four additional laboratory-confirmed cases of Marburg virus disease (MVD) have been reported in Rwanda. As of 17 October 2024, a total of 62 cases, including 15 deaths (CFR: 24.2%), have been reported. Most of the cases have been reported from the three districts in Kigali city.
Since the declaration of the outbreak on 27 September and as of 17 October, 43 confirmed cases have recovered, the remaining four cases are under care at the designated Marburg treatment center. Health workers from two health facilities in Kigali account for over 80% of confirmed cases. All new confirmed cases reported within the past week, have been associated with the two hospital clusters in Kigali. As of 17 October 2024, a total of 4486 tests for Marburg virus have been conducted, with approximately 200-300 samples being tested daily at the Rwanda Biomedical Center.
Contact tracing is underway, with over 800 contacts under follow-up as of 14 October 2024. Both contacts who travelled internationally, to Belgium and Germany, have completed the 21 days follow-up period and no longer pose a public health risk.
The source of the outbreak is still under investigation and additional information will be provided when available.
Epidemiology
MVD is a highly virulent disease that can cause haemorrhagic fever and is clinically similar to Ebola virus disease. Marburg and Ebola viruses are both members of the Filoviridae family (filovirus). People are infected with Marburg virus when they come into close contact with
Rousettus bats, a type of fruit bat, that can carry the Marburg virus and are often found in mines or caves. Marburg virus then spreads between people via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids. Health workers have previously been infected while treating patients with suspected or confirmed MVD. Burial ceremonies that involve direct contact with the body of the deceased can also contribute to the transmission of Marburg virus.
The incubation period varies from two to 21 days. Illness caused by Marburg virus begins abruptly, with high fever, severe headache and severe malaise. Severe watery diarrhoea, abdominal pain and cramping, nausea and vomiting can begin on the third day. Although not all cases present with haemorrhagic signs, severe haemorrhagic manifestations may appear between five and seven days from symptoms onset, and fatal cases usually have some form of bleeding, often from multiple areas. In fatal cases, death occurs most often between eight and nine days after symptom onset, usually preceded by severe blood loss and shock. There is currently no approved treatment or vaccine for MVD. Some candidate vaccines and therapeutics are currently under investigation.
Seventeen outbreaks of MVD have previously been reported globally. The most recent outbreaks were reported in Equatorial Guinea and the United Republic of Tanzania between February and June 2023. Additional countries that previously reported outbreaks of MVD in the African Region include Angola, the Democratic Republic of the Congo, Ghana, Guinea, Kenya, South Africa, and Uganda.
Public health response
- The Government of Rwanda is coordinating the response with support from WHO and partners.
- A surge team from WHO was deployed to support the in-country response across the functions of incident management, epidemiology, health operations, case management, infection prevention and control, health logistics, therapeutics and vaccines research, and partner coordination.
- WHO engaged with its collaborating centers and other reference laboratories and partners to support Rwanda in assessing test performance.
- Given the increasing number of survivors, WHO is supporting the Government in the establishment of a programme for survivors, by sharing technical guidance and protocols for the establishment of a national programme.
- WHO, the Government of Rwanda, and partners have launched Marburg therapeutics clinical trials.
- WHO and partners supported the Ministry of Health (MOH) in developing and finalising the national Infection Prevention and Control (IPC) operational guidance for MVD adopted/adapted from WHO-IPC guideline. This operational guidance together with IPC standard operating procedures will be rapidly disseminated to all health facilities.
- WHO supplied 12 000 personal protective equipment (PPE) which is sufficient to run a 50-bed treatment center for 30 days.
- As part of ongoing efforts to strengthen IPC, a Joint WHO and MOH IPC team has trained 520 healthcare workers on IPC measures.
- WHO has provided technical advice to public health authorities in Rwanda and at-risk countries on the implementation of evidence-informed and risk-based health measures; the strengthening of detection, reporting and management capacities at points of entry and across borders; and travel advice.
- WHO has published interim guidance on the Considerations for border health and points of entry for filovirus disease outbreaks, which applies to but is not limited to the current MVD outbreak in Rwanda.
- WHO has also published a statement advising against any travel restrictions and against any trade restrictions with Rwanda in the context of the ongoing MVD outbreak.
- WHO is providing support in surrounding countries to assess the readiness of healthcare facilities, points of entry and border communities within surrounding countries and specifically risk mapping for areas bordering Rwanda.
WHO risk assessment
Marburg virus disease (MVD) is caused by the same family of viruses (Filoviridae) that causes Ebola virus disease. MVD is an epidemic-prone disease associated with high CFR (24-88%). In the early course of the disease, MVD is challenging to distinguish from other infectious diseases such as malaria, typhoid fever, shigellosis, meningitis and other viral haemorrhagic fevers. Epidemiologic features can help differentiate between viral hemorrhagic fevers (including history of exposure to bats, caves, or mining) and laboratory testing is important to confirm the diagnosis.
With 62 confirmed cases reported, this is the third largest MVD outbreak reported, with the majority of confirmed cases reported among healthcare workers. Healthcare-associated infections (also known as nosocomial infections) of this disease can lead to further spread if not controlled early. The importance of screening all persons entering health facilities as well as inpatient surveillance for prompt identification, isolation, and notification cannot be overemphasized. This is in addition to the importance of contact identification and monitoring of all probable and confirmed cases. The source of the outbreak, the likely date of onset of the first case and additional epidemiological information on cases are still pending further outbreak investigation.
On 30 September WHO assessed the risk of this outbreak as very high at the national level, high at the regional level, and low at the global level. However, based on the evolution of the outbreak and ongoing investigations, this risk assessment may be revised. MVD is not easily transmissible (i.e. in most instances it requires contact with the body fluids of a sick patient presenting with symptoms or with surfaces contaminated with these fluids). In addition, there are ongoing public health measures in place, including active surveillance in facilities and communities, testing suspected cases, isolation and treatment of cases and contact tracing.
WHO advice
MVD outbreak control relies on using a range of interventions, including prompt isolation and case management; surveillance including active case search, case investigation and contact tracing; a laboratory service; infection prevention and control, including prompt safe and dignified burial; and social mobilization – community engagement is key to successfully controlling MVD outbreaks. Raising awareness of risk factors for Marburg virus infection and protective measures that individuals can take is an effective way to reduce human transmission. WHO advises the following risk reduction measures as an effective way to reduce MVD transmission in healthcare facilities and in communities:
- To reduce human infections and deaths, it is essential to raise community awareness about the risk factors for Marburg virus infection particularly of human-to-human transmission, and the protective measures individuals can take to minimize exposure to the virus. This includes encouraging anyone with symptoms to seek immediate care at a health facility or designated treatment center to lower the risk of community transmission and improve their chances for recovery.
- Surveillance activities, including the wide dissemination of the MVD case definition, should be strengthened in all affected districts, including contact tracing and active case finding.
- Critical infection prevention and control measures should be implemented and/or strengthened in all health care facilities, per WHO’s Infection prevention and control guideline for Ebola and Marburg disease. Health workers caring for patients with confirmed or suspected MVD should apply Transmission-based precautions in addition to: Standard precautions, including appropriate use of PPE and hand hygiene according to the WHO 5 moments to avoid contact with patient’s blood and other body fluids and with contaminated surfaces and objects
- A comprehensive strategy to manage deceased individuals in communities should be implemented in communities. Safe and dignified burials should be carried out, with strong engagement communities.
- Rapid qualitative assessments should be implemented to collect socio-behavioural data, which can then be utilized to guide the response.
- Timely laboratory testing of all suspected cases needs to be maintained and supported with a reliable sample transportation system.
- Border health readiness and response capacities should be strengthened at points of entry and in communities bordering areas reporting MVD cases and onboard conveyances, and public health advice should be provided to travellers in line with WHO’s interim guidance on considerations for border health and points of entry for filovirus disease outbreaks.
- WHO encourages all countries to send the first samples that tested positive for Marburg virus and a subset of negative samples to a WHO Collaborating Centre or a regional reference laboratory for inter-laboratory comparison.
- WHO recommends that clinical data from suspected and confirmed Marburg virus disease cases be systematically collected to improve the limited understanding of the clinical course and direct causes and risk factors for poor outcomes. This can be done by contributing anonymized data to the WHO Global Clinical Platform for viral haemorrhagic fevers.
Based on the current risk assessment, WHO advises against any travel restrictions and against any trade restrictions with Rwanda. For further information, please see
WHO advice for international traffic in relation to the Marburg virus disease outbreak in Rwanda.
...
https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON540
----------------------------------
WHO Director-General's remarks at the media briefing on the outbreak of Marburg virus disease in Rwanda – 20 October 2024
20 October 2024 Honourable Minister Dr Sabin Nsanzimana,
Members of the press,
Dear colleagues and friends,
It’s an honour to be back in Rwanda, and I thank the Minister for his hospitality, and also for his leadership in the response to the outbreak of Marburg virus disease.
Last night I also had the opportunity to meet with His Excellency President Kagame, and it is clear that he is closely engaged in the response to the outbreak.
Leadership from the highest levels of government is essential in any outbreak response, and that’s what we see here in Rwanda. Thank you Mr President and Mr Minister for your leadership.
We’re pleased to see that there have been no new cases in the past six days, and we hope that remains the case.
Yesterday
we visited the treatment centre, where there are still a few patients receiving treatment, although most are now negative for Marburg and we expect them to be discharged shortly.
We were impressed with the level of critical care for patients, which has not been used before in an outbreak of a viral haemorrhagic fever in our Continent (Africa).
Two of the patients we met had experienced all of the symptoms of Marburg, including multiple organ failure, but they were put on life support, they were successfully intubated and extubated, and are now recovering. We believe this is the first time patients with Marburg virus have been extubated in Africa. These patients would have died in previous outbreaks.
This reflects the work Rwanda has done over many years to strengthen its health system, to develop capacities for critical care and life support that can be deployed both in regular hospital care, and in emergencies. I have heard this not only from local doctors but foreign nationals working in the hospitals and treatment centres in Rwanda.
Although there are no approved vaccines or therapeutics for Marburg, we congratulate Rwanda for the speed with which it initiated trials of both vaccines and therapeutics, and we hope that these trials will help to generate the data to support approval of these products for future outbreaks.
This also demonstrates the work Rwanda has done to strengthen its regulatory system, which has been working towards reaching WHO maturity level 3. We hope the agency will reach maturity level 3 by the end of this year.
I thank the many partners who have supported these trials, including the Sabin Vaccine Institute and the University of Oxford – and I’m glad that the CEO of the Sabin Institute, Amy Finan, is able to join us today.
As you know, we have three other candidate vaccines in the pipeline, from Oxford University, Public Health Vaccines and IAVI, and I am really glad that tropical diseases like Marburg virus, which is dangerous, is getting attention, and we have vaccines in the pipeline.
Yesterday we also visited the National Command Post, and we were impressed with the way technology is being used to provide real-time information for action, and enhance operational efficiency. Borrowing the words of President Kagame, I saw smart Rwanda in action.
And we also visited the BioNTech vaccine manufacturing facility. I was here in Kigali for the groundbreaking ceremony two years ago, so I was very pleased to see the significant progress in construction.
One of the key lessons of the COVID-19 pandemic was the need to expand local production of vaccines to avoid the inequitable access to vaccines that we saw, and we’re pleased to see the way Rwanda and BioNTech are investing in local production. You know how Africa was treated when the vaccines arrived, with vaccine inequity and vaccine nationalism, and we hope these strategic investments will fix the inequity problems we faced during COVID.
So, as I said, we’re very pleased that there have been no new cases and deaths in the past six days, and I can see the outbreak is being managed under strong leadership. But we are dealing with one of the world’s most dangerous viruses, and continued vigilance is essential.
Enhanced surveillance, contact tracing and infection prevention and control measures must continue at scale until the outbreak is declared over.
WHO will continue to support the government in the response. Together with our partners we have provided technical experts, personal protective equipment, test kits and other supplies.
I thank especially the United States, the European Union and the United Kingdom for the funding they have provided to WHO and other partners.
I salute the dedicated health workers who have put themselves in harm’s way to save their colleagues, and who have continued to work despite the risks. And I honour the memory of those we have lost.
I would like to reiterate that based on a risk assessment, WHO advises against restrictions on travel or trade, because they are unnecessary and can harm Rwanda’s economy. Except harm, it does not bring anything.
Most countries have respected that advice, but some have imposed travel restrictions, and we ask those countries to reverse those restrictions.
Honourable Minister, thank you once again for your leadership, and I assure you of WHO’s complete commitment to supporting you in any way we can.
Murakoze cyane!
Thank you so much.
https://www.who.int/news-room/speec...k-of-marburg-virus-disease----20-october-2024
